Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals International, plc stock.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) is a commercial-stage biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. Headquartered in Hamilton, Bermuda, Kiniksa is at the forefront of developing immune-modulating assets aimed at addressing a spectrum of cardiovascular and autoimmune conditions.
The company’s clinical-stage product candidates include:
- ARCALYST (rilonacept): The first and only FDA-approved therapy for recurrent pericarditis, a debilitating inflammatory cardiovascular disease. ARCALYST is also approved for cryopyrin-associated periodic syndromes (CAPS) and deficiency of IL-1 receptor antagonist (DIRA).
- Mavrilimumab: An investigational monoclonal antibody targeting the GM-CSF receptor, currently being evaluated for its potential in treating giant cell arteritis and other rare cardiovascular diseases.
- Vixarelimab: An investigational monoclonal antibody inhibitor of signaling through OSMRβ.
- Abiprubart (formerly KPL-404): A humanized monoclonal antibody designed to inhibit the CD40-CD154 interaction, aimed at treating autoimmune diseases such as rheumatoid arthritis and Sjogren’s Disease.
Kiniksa’s robust pipeline is supported by significant financial strength. The company reported strong revenue growth with ARCALYST, achieving net product revenue of approximately $233.1 million in 2023, a 90% year-over-year increase. This financial performance provides a solid foundation for future investments in both commercial and clinical development projects.
Recent news highlights Kiniksa’s progress:
- In July 2023, Kiniksa announced plans to raise its 2023 ARCALYST sales guidance to between $220 million and $230 million, citing increased prescriber adoption and patient enrollments.
- In October 2023, the company reported third-quarter financial results and the completion of enrollment in the third cohort of the Phase 2 trial of KPL-404 in rheumatoid arthritis, with data expected in the first quarter of 2024.
- In February 2024, Kiniksa announced its plans to initiate a Phase 2b trial of abiprubart in Sjogren’s Disease in the second half of 2024, supported by robust ARCALYST revenue growth and a strong cash position.
For more information about Kiniksa and its pipeline, visit www.kiniksa.com.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 1:30 p.m. PT (4:30 p.m. ET). The presentation will be accessible via a live webcast on the company’s website, with a replay available within approximately 48 hours post-event. Kiniksa focuses on developing therapeutic medicines for diseases with significant unmet medical needs, featuring assets like ARCALYST®, KPL-404, and mavrilimumab, which aim to address underserved conditions by modulating immunological pathways.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced participation in the Bank of America Securities 2022 Biotech SMID Cap Conference, set for December 7, 2022, at 10:15 a.m. Eastern Time. This event will feature a fireside chat with management. Investors can access a live webcast via the company's website, with a replay available approximately 48 hours post-event. Kiniksa is dedicated to developing therapeutic medicines for serious diseases and boasts a portfolio that includes ARCALYST®, KPL-404, and mavrilimumab.
Kiniksa Pharmaceuticals, Ltd. (KNSA) will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on November 30, 2022, at 10:05 a.m. ET. A live webcast will be available on Kiniksa's website, with a replay accessible within 48 hours after the event. Kiniksa focuses on developing therapeutic medicines for debilitating diseases with significant unmet medical needs, featuring assets like ARCALYST®, KPL-404, and mavrilimumab, which target underserved conditions and modulate immunological pathways.
Kiniksa Pharmaceuticals reported Q3 2022 net revenue of $99.1 million, significantly up from $12.1 million in Q3 2021. ARCALYST net revenue was $33.4 million, with promising long-term data showing a 98.2% risk reduction in recurrent pericarditis events beyond 18 months (Hazard Ratio = 0.018, p<0.0001). The company anticipates ARCALYST full-year revenues of $115 million to $130 million and has cash reserves of $200.7 million to fund operations into at least 2025.
Kiniksa Pharmaceuticals, Ltd. (KNSA) announced a conference call and live webcast on November 1, 2022, at 8:30 a.m. ET to discuss its third quarter 2022 financial results and corporate activities. Interested participants can access the call via Kiniksa's website or register for telephone participation. A replay will be available approximately 48 hours after the event. Kiniksa focuses on developing therapeutic medicines addressing significant unmet medical needs, with assets including ARCALYST, KPL-404, and mavrilimumab.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has finalized a global license agreement with Roche and Genentech for the development of vixarelimab, a monoclonal antibody targeting oncostatin M receptor beta (OSMRβ). Kiniksa will receive $100 million upfront: $80 million within 30 days and $20 million post-delivery of drug supplies. Additionally, Kiniksa could earn up to $600 million in milestones and royalties based on sales. The company expects this funding to sustain its operations through at least 2025.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced participation in the 2022 Wedbush PacGrow Healthcare Conference on August 9, 2022, at 2:55 p.m. ET. The management will engage in a fireside chat, showcasing the company’s commitment to addressing unmet medical needs through innovative biopharmaceuticals.
A live webcast will be available on Kiniksa’s website, with a replay accessible 48 hours after the event, ensuring broad outreach to investors and stakeholders.
Kiniksa Pharmaceuticals reported Q2 2022 net revenue of $27 million from ARCALYST, marking a significant increase from $7.7 million in Q2 2021. The company expects full-year ARCALYST revenue between $115 million and $130 million. An upfront payment of $100 million is anticipated from a global license agreement with Genentech for vixarelimab, which will support operations into at least 2025. Kiniksa's net loss narrowed to $20 million from $41.6 million year-over-year. The company plans to enhance its sales team in Q4 2022.
Kiniksa Pharmaceuticals (KNSA) has entered a global licensing agreement with Roche and Genentech for the development and commercialization of vixarelimab, a monoclonal antibody targeting OSMRβ. Kiniksa will receive $100 million upfront and is eligible for up to $600 million in future milestones, along with royalties on net sales. The deal focuses on fibrotic indications where OSMRβ plays a critical role. Kiniksa plans to use the non-dilutive capital to expand its ARCALYST cardiovascular franchise. This agreement highlights Kiniksa's commitment to addressing significant unmet medical needs.
Kiniksa Pharmaceuticals, Ltd. (KNSA) will host a conference call and live webcast on August 3, 2022, at 8:30 a.m. Eastern Time to discuss its Q2 2022 financial results and corporate activities. The live webcast will be available on the company's website, with a replay accessible about 48 hours post-event. Kiniksa focuses on developing therapeutic medicines for significant unmet medical needs, with key portfolio assets including ARCALYST®, vixarelimab, KPL-404, and mavrilimumab.
FAQ
What is the current stock price of Kiniksa Pharmaceuticals International, plc (KNSA)?
What is the market cap of Kiniksa Pharmaceuticals International, plc (KNSA)?
What is Kiniksa Pharmaceuticals' primary focus?
What are the key products in Kiniksa's pipeline?
What recent achievements has Kiniksa Pharmaceuticals reported?
What is ARCALYST used for?
When was Kiniksa's latest financial report released?
What is the expected revenue for ARCALYST in 2024?
What is abiprubart (KPL-404) targeting?
What are some of the conditions Kiniksa is targeting with its therapies?
Where can I find more information about Kiniksa Pharmaceuticals?
Who should be contacted for investor and media inquiries?
